Загрузка...
Potential novel role of bevacizumab in glioblastoma and cervical cancer
The VEGF-A binding monoclonal antibody bevacizumab is a widely prescribed angiogenesis inhibitor and indicated for many types of cancer. As shown by three randomized phase 3 trials recently published in the New England Journal of Medicine, novel indications for this drug are still being explored. In...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Landes Bioscience
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4130721/ https://ncbi.nlm.nih.gov/pubmed/25046485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.29926 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|